SG Americas Securities
NERV icon

SG Americas Securities’s Minerva Neurosciences NERV Stock Holding History

SG Americas Securities’s Portfolio NERV Stock Details NERV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-1,263
Closed -$30K – 3100
2021
Q1 		$30K Buy
+1,263
New +$31.6K ﹤0.01% 3195
2020
Q3 		– Sell
-2,232
Closed -$64K – 3191
2020
Q2 		$64K Buy
2,232
+908
+69% +$53.3K ﹤0.01% 3491
2020
Q1 		$64K Buy
+1,324
New +$79.9K ﹤0.01% 3130
2017
Q2 		– Sell
-1,947
Closed -$126K – 3400
2017
Q1 		$126K Sell
1,947
-271
-12% -$21K ﹤0.01% 2815
2016
Q4 		$209K Buy
+2,218
New +$226K ﹤0.01% 2315

Other funds holding NERV

Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

SG Americas Securities's NERV Position: Q2 2021 in Review

SG Americas Securities sold out of Minerva Neurosciences (NERV) in Q2 2021, closing a stake of 1,263 shares — an estimated $30K sold.

SG Americas Securities first reported a position in NERV in Q4 2016 and held it in 5 quarters. The position peaked at $209K in Q4 2016. 68 funds tracked by Wall St. Rank hold NERV as of Q2 2021.

  • SG Americas Securities reported no remaining Minerva Neurosciences position as of Q2 2021 after selling out during the quarter.
  • SG Americas Securities sold 1,263 Minerva Neurosciences shares in Q2 2021, an estimated $30K.
  • SG Americas Securities first reported a position in Minerva Neurosciences in Q4 2016 and held it in 5 quarters.
  • SG Americas Securities's Minerva Neurosciences position peaked at $209K in Q4 2016.
  • 68 funds tracked by Wall St. Rank held Minerva Neurosciences as of Q2 2021.

Based on SG Americas Securities's 13F filing for Q2 2021, filed 12 Aug 2021.